About: High dose folic acid is a potential treatment for Pulmonary Hypertension, including when associated with COVID-19 pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High dose folic acid is a potential treatment for Pulmonary Hypertension, including when associated with COVID-19 pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	High dose folic acid is a potential treatment for Pulmonary Hypertension, including when associated with COVID-19 pneumonia
Creator	Couper, Jennifer Fengnz, Hon Mackenzie, Karen Mbchb, Geoffrey Mbchb, Jennifer Mbchb, Karen Peña, Alexia Shaw, Geoffrey Wiltshire, Esko
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Pulmonary hypertension is a significant complication for some patients with COVID-19 pneumonia, especially those requiring intensive care. Tachyphylaxis to the current therapy, inhaled nitric oxide (iNO), is also common. In vitro, folic acid directly increases nitric oxide (NO) production and extends its duration of action; effects which could be of benefit in reversing pulmonary hypertension and severe hypoxaemia. Our work has shown that, in the systemic circulation, folic acid in high dose rapidly improves nitric oxide mediated vasodilation, by activating endothelial nitric oxide synthase (eNOS). HYPOTHESIS: A similar effect of high dose folic acid on pulmonary endothelial function would be expected from the same mechanism and would lead to improvement in pulmonary perfusion. We therefore hypothesise that folic acid, 5 mg or greater, is a useful therapeutic option for pulmonary hypertension and / or refractory severe hypoxaemia, in patients with severe COVID-19 associated pneumonia in whom NO therapy is considered, with a very low risk of adverse effects.
has issue date	2020-07-26(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.110142
bibo:pmid	32759013
has license	no-cc
sha1sum (hex)	42bcc0a562e2a053514080ab92ec2eda499f1173
schema:url	https://doi.org/10.1016/j.mehy.2020.110142
resource representing a document's title	High dose folic acid is a potential treatment for Pulmonary Hypertension, including when associated with COVID-19 pneumonia
has PubMed Central identifier	PMC7382921
has PubMed identifier	32759013
schema:publication	Med Hypotheses
resource representing a document's body	covid:42bcc0a562e2a053514080ab92ec2eda499f1173#body_text
is schema:about of	named entity 'pneumonia' named entity 'Journal' named entity 'pneumonia' named entity 'Pulmonary Hypertension' named entity 'Pulmonary Hypertension' named entity 'COVID' named entity 'Pulmonary Hypertension' named entity 'potential treatment' named entity 'High dose' named entity 'endothelial function' named entity 'methyl' named entity 'hypoxaemia' named entity '5-methyltetrahydrofolate' named entity 'nitrates' named entity 'folate' named entity 'eNOS' named entity 'folic acid' named entity 'eNOS' named entity 'COVID' named entity 'nitric oxide' named entity 'iNO' named entity 'nitric oxide' named entity 'type 1 diabetes' named entity 'active form' named entity 'folic acid' named entity 'Endothelial function' named entity 'bioavailability' named entity 'endothelial dysfunction' named entity 'folic acid' named entity 'nitric oxide' named entity 'Pulmonary hypertension' named entity 'pulmonary hypertension' named entity 'severe pneumonia' named entity 'pneumonia' named entity 'folic acid' named entity 'nitric oxide' named entity 'folate' named entity 'hypoxia' named entity 'hypoxaemia' named entity 'pulmonary hypertension' named entity 'folate' named entity 'case series' named entity 'nitric oxide' named entity 'pulmonary arteries' named entity 'duration of action' named entity 'adjunctive therapy' named entity 'adverse effects' named entity 'tachyphylaxis' named entity 'genetic polymorphisms' named entity 'coronary circulation' named entity 'pulmonary hypertension' named entity 'systemic circulation' named entity 'administered orally' named entity 'COVID' named entity 'superoxide' named entity 'folic acid' named entity 'pulmonary artery' named entity 'case series' named entity 'folic acid' named entity 'nitric oxide' named entity 'iNO' named entity 'Folate' named entity 'pulmonary hypertension' named entity 'iNO' named entity 'pneumonia' named entity 'hypoxaemia' named entity 'nitric oxide' named entity 'randomised controlled trial' named entity 'systemic circulation' named entity 'vasculature' named entity 'eNOS' named entity 'Tachyphylaxis' named entity 'metabolism'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software